We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $7.48B
1-Year Est. Return 104.76%
This Fund
S&P 500
This Quarter Est. Return
+18.78%
1 Year Est. Return
+104.76%
3 Year Est. Return
+313.12%
5 Year Est. Return
+388.67%
10 Year Est. Return
+3,437.54%
AUM
$5.71B
AUM Growth
+$688M
Cap. Flow
-$39.8M
Cap. Flow %
-0.7%
Top 10 Hldgs %
24.42%
Holding
257
New
40
Increased
127
Reduced
58
Closed
20
Avg Time Held
7 quarters
Top 10 Avg Time Held
2.1 quarters
Top 20 Avg Time Held
4.2 quarters

Top Buys

Rank Stock Value
1
EQT icon
EQT Corp
EQT
+$26.6M
2
CHWY icon
Chewy
CHWY
+$26M
3
VRSK icon
Verisk Analytics
VRSK
+$25.3M
4
FTDR icon
Frontdoor
FTDR
+$24.3M
5
LRCX icon
Lam Research
LRCX
+$20.6M

Top Sells

Rank Stock Value
1
CLDX icon
Celldex Therapeutics
CLDX
+$46.7M
2
MU icon
Micron Technology
MU
+$33.6M
3
SNOW icon
Snowflake
SNOW
+$29.5M
4
INSP icon
Inspire Medical Systems
INSP
+$21.7M
5
EVH icon
Evolent Health
EVH
+$18.3M

Sector Composition

Rank Sector Weight
1 Healthcare 37.06%
2 Technology 18.81%
3 Industrials 18.23%
4 Consumer Discretionary 7.44%
5 Utilities 4.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
VRNA
1
DELISTED
Verona Pharma
VRNA
$257M 4.5%
2,715,324
-178,113
-6% -$13.2M
2023 Q3
7 quarters
GH icon
2
Guardant Health
GH
$21.9B
$180M 3.15%
3,458,963
-107,775
-3% -$4.81M
2021 Q3
15 quarters
TT icon
3
Trane Technologies
TT
$105B
$170M 2.98%
388,475
+3,196
+0.8% +$1.26M
2019 Q1
25 quarters
MIRM icon
4
Mirum Pharmaceuticals
MIRM
$5.28B
$134M 2.35%
2,637,485
+110,485
+4% +$4.92M
2022 Q3
11 quarters
INSM icon
5
Insmed
INSM
$21.2B
$120M 2.11%
1,196,494
+14,819
+1% +$1.13M
2022 Q4
10 quarters
TOST icon
6
Toast
TOST
$17.8B
$110M 1.92%
2,474,398
+4,053
+0.2% +$159K
2023 Q2
8 quarters
XMTR icon
7
Xometry
XMTR
$6.25B
$107M 1.87%
3,157,846
+4,043
+0.1% +$119K
2021 Q2
16 quarters
IRTC icon
8
iRhythm Holdings
IRTC
$3.52B
$106M 1.87%
691,573
-48,489
-7% -$6.27M
2022 Q2
12 quarters
GEV icon
9
GE Vernova
GEV
$264B
$106M 1.86%
200,407
+1,817
+0.9% +$757K
2024 Q4
2 quarters
ROP icon
10
Roper Technologies
ROP
$36.6B
$103M 1.81%
181,924
+2,277
+1% +$1.29M
2018 Q1
29 quarters
SRRK icon
11
Scholar Rock
SRRK
$5.01B
$103M 1.81%
2,913,246
+251,638
+9% +$7.9M
2023 Q4
6 quarters
LRCX icon
12
Lam Research
LRCX
$367B
$97.3M 1.7%
996,897
+259,702
+35% +$20.6M
2015 Q1
41 quarters
ODFL icon
13
Old Dominion Freight Line
ODFL
$37.5B
$97.2M 1.7%
598,831
+22,343
+4% +$3.56M
2019 Q3
23 quarters
VST icon
14
Vistra
VST
$53.8B
$94.4M 1.65%
486,042
+25,984
+6% +$3.84M
2023 Q3
7 quarters
BPMC icon
15
DELISTED
Blueprint Medicines
BPMC
$93.4M 1.64%
728,821
-133,728
-16% -$13.9M
2015 Q3
39 quarters
COLL icon
16
Collegium Pharmaceutical
COLL
$708M
$78.1M 1.37%
2,641,401
+1,854
+0.1% +$52.9K
2015 Q2
40 quarters
AXSM icon
17
Axsome Therapeutics
AXSM
$8.2B
$75.7M 1.33%
725,672
-19,178
-3% -$2.03M
2023 Q3
7 quarters
TMDX icon
18
Transmedics
TMDX
$2.77B
$73.3M 1.29%
547,355
-130,626
-19% -$14.3M
2023 Q2
8 quarters
BBNX icon
19
Beta Bionics
BBNX
$965M
$71.8M 1.26%
4,932,351
+4,332
+0.1% +$61.3K
2025 Q1
1 quarter
ARGX icon
20
argenx
ARGX
$50.5B
$69.1M 1.21%
125,383
+11,640
+10% +$6.76M
2018 Q1
29 quarters
AJG icon
21
Arthur J. Gallagher & Co
AJG
$60.1B
$67.4M 1.18%
210,571
+1,422
+0.7% +$469K
2022 Q3
11 quarters
WMB icon
22
Williams Companies
WMB
$90.5B
$66.2M 1.16%
1,044,438
+28,915
+3% +$1.71M
2021 Q4
14 quarters
LAD icon
23
Lithia Motors
LAD
$6.29B
$62.5M 1.1%
185,186
-45,003
-20% -$13.9M
2023 Q1
9 quarters
TRGP icon
24
Targa Resources
TRGP
$62.8B
$61.2M 1.07%
351,400
-99,928
-22% -$16.8M
2022 Q1
13 quarters
URI icon
25
United Rentals
URI
$66B
$60.2M 1.05%
79,871
+18,116
+29% +$12.1M
2025 Q1
1 quarter
1
2 3 4 5

Similar funds

S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
CCM
Check Capital Management Costa Mesa, California $7.52B AUM 15.3% 1-Year Est. Return
O
Ossiam Paris, France $7.54B AUM 50.81% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
FPP
Findlay Park Partners London, United Kingdom $7.41B AUM 26.32% 1-Year Est. Return
RIG
RiverFront Investment Group Richmond, Virginia $7.56B AUM 23.82% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return

Eventide Asset Management's Q2 2025 Portfolio in Review

As of Q2 2025, Eventide Asset Management held 257 positions worth $5.71B, up 14% from $5.02B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Eventide Asset Management's Q2 2025 filing shows 40 new, 127 increased, 58 reduced and 20 closed positions. Its largest new stake was Frontdoor: 483,677 shares worth $28.5M. The largest sale was Celldex Therapeutics, an estimated $46.7M.

By sector, the portfolio is most concentrated in Healthcare at 37% of assets, down from 39% a quarter earlier, followed by Technology and Industrials.

  • Eventide Asset Management's largest Q2 2025 buy was Frontdoor: 483,677 shares worth $28.5M.
  • Eventide Asset Management added most to EQT Corp in Q2 2025, an estimated $26.6M increase.
  • Eventide Asset Management's biggest Q2 2025 reduction was Celldex Therapeutics, cutting an estimated $46.7M.
  • Eventide Asset Management fully exited Krystal Biotech in Q2 2025, selling an estimated $17.3M.
  • Eventide Asset Management's ten largest holdings make up 24% of its $5.71B portfolio in Q2 2025.
  • Eventide Asset Management opened 40 new positions and closed 20 in Q2 2025.
  • Eventide Asset Management's portfolio value rose 14% quarter-over-quarter to $5.71B.

Based on Eventide Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.